173 related articles for article (PubMed ID: 35236928)
21. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors.
Zhang GM; Huang SS; Ye LX; Liu XL; Shi WH; Ren ZL; Zhou RH; Zhang JJ; Pan JX; Liu SW; Yu L; Li YL
Pharmacol Res; 2022 Oct; 184():106464. PubMed ID: 36162600
[TBL] [Abstract][Full Text] [Related]
22. Uveal melanoma: progress in molecular biology and therapeutics.
Li Y; Shi J; Yang J; Ge S; Zhang J; Jia R; Fan X
Ther Adv Med Oncol; 2020; 12():1758835920965852. PubMed ID: 33149769
[TBL] [Abstract][Full Text] [Related]
23. Identifying biomarkers and novel therapeutic targets in uveal melanoma.
Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
J Dtsch Dermatol Ges; 2024 Jan; 22(1):29-32. PubMed ID: 37902386
[TBL] [Abstract][Full Text] [Related]
24. Uveal melanoma: epidemiology, etiology, and treatment of primary disease.
Krantz BA; Dave N; Komatsubara KM; Marr BP; Carvajal RD
Clin Ophthalmol; 2017; 11():279-289. PubMed ID: 28203054
[TBL] [Abstract][Full Text] [Related]
25. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma.
Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD
BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891
[TBL] [Abstract][Full Text] [Related]
26. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
27. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
28. Genetic Aspects of Conjunctival Melanoma: A Review.
Chang E; Demirci H; Demirci FY
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761808
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; NĂ©mati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
30. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
31. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
[TBL] [Abstract][Full Text] [Related]
32. Targeting Epigenetic Modifications in Uveal Melanoma.
Chokhachi Baradaran P; Kozovska Z; Furdova A; Smolkova B
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32726977
[TBL] [Abstract][Full Text] [Related]
33. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
[TBL] [Abstract][Full Text] [Related]
34. Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma.
Mallone F; Sacchetti M; Lambiase A; Moramarco A
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32992823
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
36. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
37. miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma.
Li J; Liu X; Li C; Wang W
J Cell Biochem; 2019 Aug; 120(8):12412-12421. PubMed ID: 30825222
[TBL] [Abstract][Full Text] [Related]
38. The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".
Strub T; Ballotti R; Bertolotto C
Theranostics; 2020; 10(4):1777-1797. PubMed ID: 32042336
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy for uveal melanoma.
Triozzi PL; Eng C; Singh AD
Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
[TBL] [Abstract][Full Text] [Related]
40. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
Steeb T; Wessely A; Ruzicka T; Heppt MV; Berking C
Eur J Cancer; 2018 Nov; 103():41-51. PubMed ID: 30205280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]